Premium
Effect of propranolol on secretin‐induced gastrin release and secretin‐induced tachycardia in patients with the Zollinger‐Ellison syndrome
Author(s) -
GOLDSCHMIEDT M.,
REDFERN J. S.,
FELDMAN M.
Publication year - 1990
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1990.tb00479.x
Subject(s) - secretin , medicine , propranolol , zollinger ellison syndrome , gastrin , tachycardia , endocrinology , gastroenterology , gastrinoma , pancreas , secretion
SUMMARY The mechanism for secretin‐induced gastrin release in the Zollinger‐Ellison syndrome is uncertain. We evaluated whether the stimulatory effect of intravenous secretin on gastrin release was partly mediated through a beta‐adrenergic stimulatory mechanism. Serum gastrin concentrations and heart rate were monitored in six patients with the Zollinger‐Ellison syndrome. Secretin (2 clinical units/kg) increased mean serum gastrin concentrations from 1558 pg/ml basally to a peak of 3683 pg/ml (136% above baseline). This increase was not altered by pretreatment with 2 mg of propranolol intravenously, a dose which in previous studies blocked terbutaline‐induced gastrin release. Secretin increased heart rate by 14 beats/min (20% above base‐line) and this also was not altered by propranolol pretreatment. Thus, the stimulatory effects of secretin on gastrinoma cells and the heart do not appear to be mediated by beta‐adrenergic receptors.